NTLA Intellia Therapeutics, Inc.

NTLA Intellia Therapeutics, Inc.

Healthcare · Biotechnology

Desk view

PassedIntellia is a clinical-stage gene-editing biotech with no approved commercial product — pre-revenue biotech lottery. (2026-09-22)
Basis Logged decision
Updated

Market read

Scan convergence 1 scan as of 2026-10-16 1 bear converging

POC $12.60 · VWAP $12.98 · -12.0% vs 12m avg buyer

downtrend vol: normalchurn: quiet as of

Insiders quiet 0 buy / 0 sell · Form 4, 90d

Coverage

NTLA Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist NTLA belongs to, members best 30-day change first — NTLA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@biotech
@ibb
@biotech-scan
@insider-universe
View watchlist →
MRNA+49.7% -7.8%1d -3.1%7d SHOP+30.4% -4.8%1d -0.8%7d PINS+17.5% -3.5%1d +2.4%7d ISRGE+11.6% -0.3%1d +0.7%7d LLY+10.5% +0.4%1d +6.6%7d ZS+8.3% -5.9%1d -11.3%7d MSFT+7.9% -1.9%1d -1.1%7d ESTC+7.9% -5.7%1d -6.6%7d DDOG+7.1% -7.2%1d -15.7%7d PLTR+6.7% -7.2%1d -11.0%7d TMO+6.4% -0.9%1d +4.9%7d META+5.3% -3.7%1d -1.3%7d UI+5.3% -2.8%1d -8.6%7d COIN+5.3% -5.8%1d -3.5%7d CEG+4.6% -1.3%1d -9.0%7d RBLX+4.5% -3.1%1d +3.0%7d ABNB+3.7% -0.3%1d +4.7%7d AFRM+3.4% -2.5%1d -8.3%7d AAPL+3.3% +0.4%1d +2.0%7d AMD+3.2% -6.0%1d -13.1%7d ASML+2.5% -1.0%1d -7.8%7d ZM+2.5% -4.4%1d -3.6%7d TWLO+2.3% -10.6%1d -15.6%7d ASAN+2.2% -5.4%1d -2.1%7d AMZN+1.6% -1.9%1d -4.7%7d NOW+1.5% -4.4%1d +0.8%7d HIMS+0.3% -4.5%1d -9.2%7d NVDA+0.1% -1.4%1d -6.6%7d NTLA-0.6% +0.7%1d -12.6%7d GOOGL-0.7% -2.5%1d -3.1%7d MRVL-0.8% -5.6%1d -17.2%7d UBER-0.9% -1.3%1d -1.6%7d TSLA-0.9% -2.1%1d -7.3%7d TSM-1.2% -2.3%1d -9.0%7d FTNT-1.5% -7.0%1d -13.2%7d VRTX-2.6% -1.8%1d -2.0%7d AVGO-3.2% -4.5%1d -9.1%7d CRM-3.9% -2.5%1d +5.0%7d U-4.1% -6.8%1d -13.8%7d FSLY-4.5% -10.4%1d -23.3%7d IBKR-4.7% -3.9%1d -5.9%7d CRSP-5.7% -4.4%1d -7.8%7d CRWD-5.8% -7.0%1d -17.3%7d ARM-6.6% -6.9%1d -14.4%7d QCOM-6.9% -3.5%1d -1.9%7d SNOW-7.3% -8.4%1d -16.8%7d NFLXE-7.7% -2.9%1d +0.3%7d BNTX-8.5% -2.8%1d -9.5%7d NET-8.7% -6.3%1d -17.9%7d PANW-9.0% -7.6%1d -18.3%7d FSLR-9.7% -3.5%1d -2.9%7d MDB-10.3% -7.9%1d -12.5%7d INTC-11.1% -5.8%1d -14.2%7d SOFI-13.6% -3.6%1d -7.9%7d ENPH-13.9% -0.7%1d -6.7%7d AKAM-16.0% -4.9%1d -17.9%7d BE-18.0% -6.3%1d -21.1%7d DOCN-20.3% -9.8%1d -26.8%7d EOSE-53.8% -15.7%1d -27.8%7d

Desk commentary

Authored analysis and challenge notes tied to NTLA.

1

Next earnings NTLA reports in 19 days Nov 5

Last report Aug 6

Reported the quarter ending 2026-06-30: revenue $8M, diluted EPS -$0.80, net income -$107M (SEC filing). Across the print the stock moved +8.8% (close before → first close after).

full note →

Against street estimates

How NTLA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 10 quarters · newest report Aug 6 · projection Oct 16

Result
Aug 6 -0.78-0.80-1.9%In line
May 11 -0.90-0.81+9.8%Beat
Feb 26 -0.96-0.83+13.7%Beat
Nov 6 '25 -0.98-0.92+6.6%Beat
Aug 7 '25 -1.01-0.98+2.5%Beat
May 8 '25 -1.27-1.10+13.5%Beat
Feb 27 '25 -1.32-1.27+3.5%Beat
Nov 7 '24 -1.37-1.34+2.1%Beat

News (last pull)

Headlines about NTLA from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 25 days ago · Sep 22

“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.

Types
Aug 6 Catalyst NTLA earnings
May 7 Catalyst NTLA earnings